Generic

Olmesartan Medoxomil + Hydrochlorothiazide

Indications

The combination of Olmesartan Medoxomil and Hydrochlorothiazide is used to treat hypertension.

Pharmacology

Angiotensin-II shaped from angiotensin-I in a response catalyzed by angiotensin-converting chemical (Pro), could be a powerful vasoconstrictor, the essential vasoactive hormone of the renin-angiotensin framework and an imperative component within the pathophysiology of hypertension. It too invigorates aldosterone discharge by the adrenal cortex. Olmesartan squares the vasoconstrictor and aldosterone-secreting impacts of angiotensin-II by specifically blocking the official of angiotensin-II to the AT 1 receptor found in numerous tissues (e.g. vascular smooth muscle, adrenal organ). In-vitro-binding thinks about demonstrating that Olmesartan could be a reversible & competitive inhibitor of AT 1 receptor. Olmesartan does not hinder Pro (kinase-I, the protein that changes from angiotensin-I to angiotensin-II and corrupts bradykinin).

Hydrochlorothiazide may be a thiazide diuretic. Thiazides influence the renal tubular instruments of electrolyte reabsorption, straightforwardly expanding the excretion of Sodium and Chloride in proportionate sums. By implication, the diuretic activity of Hydrochlorothiazide diminishes plasma volume with resulting increments in plasma renin movement, increments in Aldosterone discharge & urinary Potassium misfortune, and diminishes serum Potassium. The renin-aldosterone connection is interceded by angiotensin-II. So, co-administration of an angiotensin-II receptor opponent tends to turn around the potassium misfortune related to these diuretics.

Dosage & Administration

Hypertension: The usual starting dose is 20/12.5 mg one tablet once daily. Dosing should be individualized. Depending on the blood pressure response, the dose may be titrated at intervals of 2-4 weeks to two tablets 40/25 once daily.

Interaction

In investigations in which Olmesartan Medoxomil was co-administered with hydrochlorothiazide, digoxin, or warfarin in healthy volunteers, no significant medication interactions were reported. Because Olmesartan medoxomil is not metabolized by the cytochrome P450 system and has no effect on P450 enzymes, it is unlikely that it would interact with medications that inhibit, induce, or metabolize those enzymes.

Hydrochlorothiazide: The following medicines may interact with Thiazide diuretics if used at the same time:
Benzodiazepines, barbiturates, or narcotics: It’s possible that orthostatic hypotension will be exacerbated.
Antidiabetic medicines (oral agents and Insulin): Antidiabetic drug dosage may need to be adjusted.
Other antihypertensive medications include: The effect is additive.
ACTH, corticosteroids
Lithium.

Contraindications

Patients who are hypersensitive to either component of this medication should not use the combination of Olmesartan and Hydrochlorothiazide. This medication is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived pharmaceuticals due to the Hydrochlorothiazide component.

Side Effects

The drug Olmesartan-hydrochlorothiazide was well tolerated, with an adverse event rate compared to placebo. Vertigo, coughing, back discomfort, rash, weakness, transient blurred vision, diarrhea, headache, and urinary tract infection were all moderate, transient events that had no relation to the dose of Olmesartan-hydrochlorothiazide.

Pregnancy & Lactation

The safety and effectiveness of the drug in nursing mothers and pregnant women has yet to be determined. During these circumstances, the medicine should be stopped.

Precautions & Warnings

To detect probable electrolyte imbalances such as hypokalemia, hyponatremia, and hypochloremic alkalosis, periodic testing of serum electrolytes should be performed at appropriate intervals.
Certain people on thiazide treatment may develop hyperuricemia.
Renal function is impaired.

Therapeutic Class

Combined antihypertensive preparations

Storage Conditions

Protect from light and moisture by storing in a cool, dry location. Keep out of children’s reach.

Pharmaceutical Name

Opsonin Pharma Ltd.